Hae Suk Cheong

Dr. Hae Suk Cheong

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2011 in Critical Care
Verified
Journal Article
Open access
PDF file
KJKyong Mi Joung
Kyong Mi Joung
JLJeong-A Lee
Jeong-A Lee
SMSoo-Youn Moon
Soo-Youn Moon
HCHae Suk Cheong
Hae Suk Cheong
EJEun-Jeong Joo
Eun-Jeong Joo
KPKyong Ran Peck
Kyong Ran Peck
Introduction: De-escalation therapy is a strategy currently used for the management of nosocomial pneumonia. In this study, we evaluated clinical outcomes and risk factors related to de-escalation therapy in patients with intensive care unit (ICU)-acquired pneumonia. Methods: This was a retrospective observational cohort study of ICU patients who developed pneumonia more than 48 hours after admission to the ICU at Samsung Medical Center from September 2004 to December 2007. Results: The 137 patients comprised 44 (32.1%) who received de-escalation therapy and 93 in the non-de-escalation group. The de-escalation group showed a lower pneumonia-related mortality rate than the non-de-escalation group by day 14 (2.3% vs. 10.8%, respectively; P = 0.08) and by day 30 (2.3% vs. 14%, respectively; P = 0.03) after the diagnosis of pneumonia. The variables independently associated with ICU-acquired pneumonia-related mortality included the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and the modified Clinical Pulmonary Infection Score (CPIS) after 5 days with pneumonia. The non-de-escalation group had significantly higher APACHE II score and modified CPIS after 5 days with ICU-acquired pneumonia compared to the de-escalation group. Among all patients, 20.4% (28 of 137) had negative cultures for pathogens, and 42.9% (12 of 28) received de-escalation therapy. The latter 12 patients received de-escalation therapy and survived 30 days after the diagnosis of pneumonia. Conclusions: Patients in the de-escalation group showed a significantly lower mortality rate compared to patients in the non-de-escalation group. De-escalation therapy can be safely provided to patients with ICU-acquired pneumonia if they are clinically stable by day 5, even in those whose respiratory specimen cultures yield no specific pathogens.

Verified
Journal Article
Open access
PDF file
HKHan-Na Kim
Han-Na Kim
EJEun-Jeong Joo
Eun-Jeong Joo
HCHae Suk Cheong
Hae Suk Cheong
YKYejin Kim
Yejin Kim
HKHyung-Lae Kim
Hyung-Lae Kim
SRSeungho Ryu
Seungho Ryu
Gut dysbiosis is regarded as a pathogenetic factor of nonalcoholic fatty liver disease (NAFLD), but its role in NAFLD persistence is unknown. We investigated the influence of the gut microbiota on persistent NAFLD. This cohort study included 766 subjects with 16S ribosomal RNA (rRNA) gene sequencing data from fecal samples at baseline who underwent repeated health check-up examinations. Fatty liver was determined using ultrasound at baseline and follow-up. Participants were categorized into four groups: none (control), developed, regressed, or persistent NAFLD. The persistent NAFLD group had lower richness compared with the control group. Significant differences were also found in both non-phylogenic and phylogenic beta diversity measures according to NAFLD persistence. Pairwise comparisons indicated that taxa abundance mainly differed between the control and persistent NAFLD groups. A relative high abundance of Fusobacteria and low abundance of genera Oscillospira and Ruminococcus of the family Ruminococcaceae and genus Coprococcus of the family Lachnospiraceae were found in the persistent NAFLD group. Based on the functional predictions, pathways related to primary and secondary bile acid biosynthesis were highly detected in the persistent NAFLD group compared with the control group. These findings support that the composition of the gut microbiome associated with dysregulation of bile acid biosynthetic pathways may contribute to the persistence of NAFLD. This is the first cohort study to demonstrate the influence of microbiota on persistent NAFLD. Our findings may help identify potential targets for therapeutic intervention in NAFLD.

2 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YYYeojun Yun
Yeojun Yun
YCYoosoo Chang
Yoosoo Chang
HKHan-Na Kim
Han-Na Kim
SRSeungho Ryu
Seungho Ryu
MKMin-Jung Kwon
Min-Jung Kwon
EJEun-Jeong Joo
Eun-Jeong Joo
The changes in the gut microbiota of healthy hepatitis B virus (HBV) carriers, including asymptomatic and non-cirrhotic subjects, have been rarely scrutinized. From 1463 faecal samples in health examinees, in total 112 subjects, including 36 hepatitis B surface antigen (HBsAg)-positive and 76 control subjects, were included. Twenty-eight of 36 HBsAg-positive individuals (78%) showed normal alanine aminotransferase (ALT) levels (normal ALT group), whereas eight subjects exhibited elevated ALT levels (22%, high ALT group). By using 16S rRNA gene sequencing, the distance between normal and high ALT groups among HBsAg-positive subjects showed a significant separation after the pairwise comparison of weighted UniFrac distance (permutational analysis of variance q-value = 0.039), when compared with the distances to the control group. In comparison with the control group, the normal ALT group had Anaerostipes as a significant taxon that showed a positive association (Coefficient (Coef.) = 0.028, q = 0.039). Desulfovibrio (Coef. = 0.54, q = 0.014) and Megasphaera (Coef. = 1.41, q = 0.030) showed positive correlations, and Acidaminococcus (Coef. = −1.31, q = 4.15 × 10−75) exhibited a negative correlation with high ALT level. Gut microbial composition was different according to HBV-induced serum ALT levels, indicative of a potential link between gut and liver metabolism.

11 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HCHae Suk Cheong
Hae Suk Cheong
SKSo Yeon Kim
So Yeon Kim
YWYu Mi Wi
Yu Mi Wi
KPKyong Ran Peck
Kyong Ran Peck
Kwan Soo KoKwan Soo Ko
Kwan Soo Ko
Heteroresistance may pose a threat to the prognosis of patients following colistin treatment. We investigated colistin heteroresistance in Klebsiella pneumoniae isolates from South Korea. Among 252 K. pneumoniae blood isolates, 231 were susceptible to polymyxins. Heteroresistance to colistin was determined using population analysis profiles, disk diffusion assays, and E-test strip tests for the susceptible isolates. As a result, we identified three colistin-heteroresistant K. pneumoniae isolates belonging to separate clones (ST11, ST461, and ST3217) by multilocus sequence typing analysis. Two colistin-resistant subpopulations were selected from each heteroresistant isolate in either disk diffusion testing or E-testing. Two resistant subpopulations from the same isolate exhibited different amino acid substitutions in the two-component regulatory systems PmrAB and PhoPQ. An in vitro time–kill assay showed that meropenem combined with colistin had a 1× minimum inhibitory concentration bactericidal effect against a multidrug-resistant, colistin-heteroresistant isolate.

1 January 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
HCHae Suk Cheong
Hae Suk Cheong
KPKyung-Hwa Park
Kyung-Hwa Park
HKHong Bin Kim
Hong Bin Kim
SKShin-Woo Kim
Shin-Woo Kim
BKBongyoung Kim
Bongyoung Kim
KPKorean Society For Healthcare-Associated Infection Control And Prevention
Korean Society For Healthcare-Associated Infection Control And Prevention
Cheong HS, et al. Infect Chemother. 2022 Dec;54(4):637-673. https://doi.org/10.3947/ic.2022.0171

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHae Suk Cheong
Hae Suk Cheong
KKKi Tae Kwon
Ki Tae Kwon
SHSoyoon Hwang
Soyoon Hwang
SKShin-Woo Kim
Shin-Woo Kim
HCHyun-Ha Chang
Hyun-Ha Chang
Ji Woong SonJi Woong Son
Ji Woong Son
Cheong HS, et al. J Korean Med Sci. 2022 Feb;37(6):e49. https://doi.org/10.3346/jkms.2022.37.e49